DirectTrust and the Digital Therapeutics Alliance announced this week that they will collaborate on a certification program designed to test the effectiveness and security of digital therapeutics applications and platforms number.
WHY IS IT IMPORTANT?
Together, the two groups will collaborate to establish a review regime that builds on existing DirectTrust programs to provide independent review of medical applications for safety and transparency, protecting privacy privacy, compliance with interoperability regulations and best practices, etc., according to DTA, which is holding its annual summit this week.
The aim is to “establish a rigorous certification program specifically for DTx products, which will build upon DirectTrust’s established and widely adopted Security and Privacy certification program widely,” said Andy Molnar, CEO of Digital Therapeutics Alliance.
Meanwhile, DirectTrust already has a series of programs designed to evaluate the large and extremely diverse digital health application and platform market.
“Our Health Apps Program values privacy and security, while the CARIN Code of Conduct is for consumer-facing apps,” said Scott Stuewe, president and CEO of DirectTrust. used to evaluate transparency and data usage outside of HIPAA.” “Additionally, our UDAP programs validate efficient, scalable connections to national health networks using the FHIR standard.”
DTA will lead the development of criteria for the new program – expected to launch later this year – while DirectTrust will manage it.
A focus group consisting of stakeholders with expertise and interest in clinical effectiveness will also be established as a subgroup of the DirectTrust Criteria Panel and anyone interested in applying the Criteria Panel or participating as a beta organization for accreditation are encouraged to visit the DirectTrust website or email [email protected].
BIGGER TREND
In recent years, DTA has created a series of collaborative, validated assets to identify and evaluate DTx products. Those frameworks – such as the product library incorporating core industry principles and the DTx Value Assessment and Integration Guide – will serve as the foundation for new program evaluation criteria.
DTA also directed stakeholders to the recent clinical evidence paper “Setting the Stage for Fit-For-Purpose DTx Evidence Standards”.
Digital therapeutics are proving their value, at home and at the service provider, and offering new approaches to managing a range of conditions, including ADHD, generalized anxiety general, multiple sclerosis and many other diseases.
Meanwhile, DTA is working to ensure the effectiveness of those countless apps and tools, while also encouraging technology developers to focus on health equity.
Meanwhile, among many recent initiatives, DirectTrust has focused on interoperability use cases such as a secure cloud fax standard.
ON PROFILE
“As the digital therapeutics industry grows, more and more U.S. clinicians, provider systems, health plans, employers and patients are evaluating how to best integrate DTx products into their care plan to provide the highest quality of care.” “With a large number of products that meet many stringent clinical requirements, it is important that we set high standards to build trust.”
“With the creation of this new certification to evaluate the clinical effectiveness of Digital Therapeutics, organizations will be able to choose the program(s) that fit their business model,” Steuwe added.
Mike Miliard is the executive editor of Healthcare IT News
Email the writer: [email protected]
Healthcare IT News is a HIMSS publication.
